Craft

Axcella Health

Stock Price

$0.4

2023-12-29

Market Capitalization

$1.2 M

2023-12-29

Axcella Health Summary

Company Summary

Overview
Axcella Health is a biotechnology company that researches and develops novel multifactorial interventions to support health and address dysregulated metabolism. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy, AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease, AXA2678 for use in treating immobilization-induced acute muscle atrophy, and AXA4010 to target multiple biological pathways. 
Type
Public
Status
Active
Founded
2010
HQ
Cambridge, MA, US | view all locations
Website
http://www.axcellahealth.com
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • David R. Epstein

    David R. Epstein, Director

    • Bill Hinshaw

      Bill Hinshaw, President & Chief Executive Officer, Director

      • Alison Schecter

        Alison Schecter, President, Research and Development

        • William D. Baird

          William D. Baird, Director

          LocationsView all

          1 location detected

          • Cambridge, MA HQ

            United States

            5 Memorial Dr

          Axcella Health Financials

          Summary Financials

          Net income (Q2, 2023)
          ($3.4M)
          Cash (Q2, 2023)
          $8.9M
          EBIT (Q2, 2023)
          ($3.5M)
          Enterprise value
          ($6.3M)

          Footer menu